Cancer Research and Treatment

ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition

Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, Wei-Yun Lai, Jikui Guan, Joel Johansson, Eva Jennische, Alexander Schmidt, Yeshwant Kurhe, Jonatan L. Gabre, Agata Aniszewska, Anneli Strömberg, Mats Bemark, Michael N. Hall, Jimmy Van den Eynden, Bengt Hallbe

Proceedings of the National Academy of Sciences.2024;[Epub] CrossRef

Elevated Expression of LGR5 and WNT Signaling Factors in Neuroblastoma Cells With Acquired Drug Resistance

John Clark-Corrigall, Svetlana Myssina, Martin Michaelis, Jindrich Cinatl, Shafiq Ahmed, Jane Carr-Wilkinson

Computational intelligence analysis of high-risk neuroblastoma patient health records reveals time to maximum response as one of the most relevant factors for outcome prediction

Davide Chicco, Riccardo Haupt, Alberto Garaventa, Paolo Uva, Roberto Luksch, Davide Cangelosi

European Journal of Cancer.2023; 193: 113291. CrossRef

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma

Aleksandra Wieczorek, Anna Zaniewska-Tekieli, Karoline Ehlert, Katarzyna Pawinska-Wasikowska, Walentyna Balwierz, Holger Lode

Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease

Seyed M. Rahavi, Maryam Aletaha, Ali Farrokhi, Amanda Lorentzian, Philipp F. Lange, Christopher A. Maxwell, Chinten James Lim, Gregor S. D. Reid

International Journal of Molecular Sciences.2023; 24(15): 12071. CrossRef

Challenging diagnosis of Mycolicibacterium cosmeticum/canariasense infection: A case report and literature review

Daniel Grupel, Orly Sagi, Israel Nissan, Rona Grossman, Motro Yair, Jacob Moran-Gilad, Dana Danino

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2023; 33: 100393. CrossRef

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data

Aleksandra Wieczorek, Urszula Żebrowska, Marek Ussowicz, Agnieszka Sokół, Marzena Stypińska, Bożenna Dembowska-Bagińska, Katarzyna Pawińska-Wąsikowska, Walentyna Balwierz

Journal of Clinical Medicine.2023; 12(16): 5252. CrossRef

Characterization and therapeutic perspectives of differentiation-inducing therapy in malignant tumors

Kangwei Zhu, Yuren Xia, Xindi Tian, Yuchao He, Jun Zhou, Ruyu Han, Hua Guo, Tianqiang Song, Lu Chen, Xiangdong Tian

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

Juan Muñoz, Cristina Larrosa, Saray Chamorro, Sara Perez-Jaume, Margarida Simao, Nazaret Sanchez-Sierra, Amalia Varo, Maite Gorostegui, Alicia Castañeda, Moira Garraus, Sandra Lopez-Miralles, Jaume Mora

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation

Diana Treis, Ganesh Umapathy, Susanne Fransson, Jikui Guan, Patricia Mendoza-García, Joachim T. Siaw, Sandra Wessman, Lena Gordon Murkes, Jakob J. E. Stenman, Anna Djos, Lotta H. M. Elfman, John Inge Johnsen, Bengt Hallberg, Ruth H. Palmer, Tommy Martinss

High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy

Current Cancer Therapy Reviews.2022; 18(1): 14. CrossRef

Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma

Zijun Yan, Qiming Liu, Ziyang Cao, Jinxia Wang, Hongyang Zhang, Jiangbin Liu, Lin Zou

Frontiers in Neuroinformatics.2022;[Epub] CrossRef

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas

Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience

P. Berlanga, C. Pasqualini, U. Pötschger, C. Sangüesa, M.R. Castellani, A. Cañete, R. Luksch, M. Elliot, G. Schreier, M. Kropf, D. Morgenstern, V. Papadakis, S. Ash, E. Ruud, P. Brock, A. Wieczorek, P. Kogner, T. Trahair, P. Ambros, T. Boterberg, V. Caste

European Journal of Cancer.2021; 144: 1. CrossRef

Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta

Richa Jain, Amita Trehan, Prema Menon, Rakesh Kapoor, Nandita Kakkar, Srinivasan Radhika, Akshay Kumar Saxena, Bhagwant Rai Mittal, Neelam Varma, Ram Samujh, Deepak Bansal

Pediatric Hematology and Oncology.2021; 38(4): 291. CrossRef

Christine Chung, Tom Boterberg, John Lucas, Joseph Panoff, Dominique Valteau‐Couanet, Barbara Hero, Rochelle Bagatell, Christine E. Hill‐Kayser

Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan

Yuya Saito, Mitsuyoshi Urashima, Yoshiyuki Takahashi, Atsushi Ogawa, Chikako Kiyotani, Yuki Yuza, Katsuyoshi Koh, Kenichiro Watanabe, Yoshiyuki Kosaka, Hiroaki Goto, Atsushi Kikuta, Keiko Okada, Yuhki Koga, Junya Fujimura, Masami Inoue, Atsushi Sato, Yosh

Bone Marrow Transplantation.2021; 56(9): 2173. CrossRef

Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma

Paolo Uva, Maria Carla Bosco, Alessandra Eva, Massimo Conte, Alberto Garaventa, Loredana Amoroso, Davide Cangelosi

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients

T. Bauters, D. Heenen, K. Norga, A. Van Damme, A. Uyttebroeck, G. Laureys

European Journal of Pediatrics.2021; 180(9): 3067. CrossRef

Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma

Case Reports in Pediatrics.2021; 2021: 1. CrossRef

Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study

Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Martin Elliott, Shifra Ash, Godfrey C. F. Chan, Geneviève Laureys, Maja Beck-Popovic, Kim Vettenranta, Walentyna Balwierz, Henrik Schroeder, Cormac Owens, Ma

Journal of Clinical Oncology.2021; 39(23): 2552. CrossRef

Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics

Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml, Silvie Rimpelová

Extending the Applicability of In Ovo and Ex Ovo Chicken Chorioallantoic Membrane Assays to Study Cytostatic Activity in Neuroblastoma Cells

Miguel Angel Merlos Rodrigo, Berta Casar, Hana Michalkova, Ana Maria Jimenez Jimenez, Zbynek Heger, Vojtech Adam

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim Tetteh Siaw, Arne Claeys, Jonatan L. Gabre, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer

Association of PARP1 polymorphisms with response to chemotherapy in patients with high‐risk neuroblastoma

Marianna Avitabile, Vito Alessandro Lasorsa, Sueva Cantalupo, Antonella Cardinale, Flora Cimmino, Annalaura Montella, Dalila Capasso, Riccardo Haupt, Loredana Amoroso, Alberto Garaventa, Alessandro Quattrone, Maria Valeria Corrias, Achille Iolascon, Mario

Journal of Cellular and Molecular Medicine.2020; 24(7): 4072. CrossRef

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ladenstein, Pötschger, Valteau-Couanet, Luksch, Castel, Ash, Laureys, Brock, Michon, Owens, Trahair, Chi Fung Chan, Ruud, Schroeder, Beck-Popovic, Schreier, Loibner, Ambros, Holmes, Castellani, Gaze, Garaventa, Pearson, Lode

Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR

F. Berthold, A. Faldum, A. Ernst, J. Boos, D. Dilloo, A. Eggert, M. Fischer, M. Frühwald, G. Henze, T. Klingebiel, C. Kratz, B. Kremens, B. Krug, I. Leuschner, M. Schmidt, R. Schmidt, R. Schumacher-Kuckelkorn, D. von Schweinitz, F.H. Schilling, J. Theisse

Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma

S. L. George, V. Parmar, F. Lorenzi, L. V. Marshall, Y. Jamin, E. Poon, P. Angelini, L. Chesler

Journal of Experimental & Clinical Cancer Research.2020;[Epub] CrossRef

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study

Keith Holmes, Ulrike Pötschger, Andrew D. J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E. Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean

Journal of Clinical Oncology.2020; 38(25): 2902. CrossRef

Development of differentiation modulators and targeted agents for treating neuroblastoma

Zegao Jin, Yang Lu, Yizhe Wu, Jinxin Che, Xiaowu Dong

European Journal of Medicinal Chemistry.2020; 207: 112818. CrossRef

A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma

Expert Opinion on Orphan Drugs.2020; 8(12): 497. CrossRef

Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects

Yao Wang, Jeffrey H. Stear, Ashleigh Swain, Xing Xu, Nicole S. Bryce, Michael Carnell, Irina B. Alieva, Vera B. Dugina, Timothy P. Cripe, Justine Stehn, Edna C. Hardeman, Peter W. Gunning

Molecular Cancer Research.2020; 18(7): 1074. CrossRef

Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction

Jasmin D. Haslbauer, Sarah Lindner, Gesine Bug, Eike Nagel, Valentina O. Puntmann

Current Cardiovascular Imaging Reports.2019;[Epub] CrossRef

Therapy intensification in high-risk neuroblastoma patients with poor response to standard induction: experience of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

T. V. Shamanskaya, D. Y. Kachanov, A. V. Dumacheva, M. V. Teleshova, D. V. Shevtcov, T. V. Sergeeva, A. M. Syleimanova, R. A. Moiseenko, Y. N. Likar, . Kailash, S. R. Varfolomeeva

Pediatric Hematology/Oncology and Immunopathology.2019; 18(4): 19. CrossRef

Molecular mechanisms and therapeutic targets in neuroblastoma

John Inge Johnsen, Cecilia Dyberg, Susanne Fransson, Malin Wickström

Pharmacological Research.2018; 131: 164. CrossRef

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma

Joshua Felgenhauer, Laura Tomino, Julia Selich-Anderson, Emily Bopp, Nilay Shah

Prise en charge des neuroblastomes de haut risque : l’expérience du groupe européen SIOPEN

Dominique Valteau-Couanet, Gudrun Schleiermacher, Sabine Sarnacki, Claudia Pasqualini

Novel Therapies for Relapsed and Refractory Neuroblastoma

Investigational drugs in phase II clinical trials for the treatment of neuroblastoma

Loredana Amoroso, Riccardo Haupt, Alberto Garaventa, Mirco Ponzoni

Expert Opinion on Investigational Drugs.2017; 26(11): 1281. CrossRef